UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of: March 2015
Commission file number: 001-36578
BIO BLAST PHARMA LTD.
(Translation of registrant's name into English)
37 Dereh Menechem Begin St., 15th Floor
Tel Aviv 6522042 Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(1):_____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulations S-T Rule 101(b)(7):_____
CONTENTS
This Report of Foreign Private Issuer on Form 6-K of the registrant consists of the press release issued by the registrant on March 12, 2015, announcing that the U.S. Food and Drug Administration has granted clearance for the registrant to proceed with an Investigational New Drug Application for the development of its drug candidate Cabaletta in patients with Oculophryngeal Muscular Dystrophy.
Exhibit No.
| 99.1 | Press Release issued by Bio Blast Pharma Ltd. on March 12, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Bio Blast Pharma Ltd.
| ||
| Name: Colin Foster | ||
| Chief Executive Officer and President |
Date: March 12, 2015